Financials in USD. Standardized financial statements.
A compact view of how Rejuvel Bio-Sciences, Inc. turns revenue into operating income and net income.
| Metric | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 |
|---|---|---|---|---|---|
| Revenue? | $94,096 | $51,559 | $7,979 | $1,500 | $0 |
| Revenue Growth? | +82.5% | +546.2% | +431.9% | 0.0% | 0.0% |
| Cost of Revenue? | $83,304 | $26,805 | $3,869 | $625 | $0 |
| Gross Profit? | $10,792 | $24,754 | $4,110 | $875 | $0 |
| Gross Margin? | +11.5% | +48.0% | +51.5% | +58.3% | 0.0% |
| Operating Expenses? | $697,997 | $554,460 | $681,875 | $228,713 | $24,871 |
| Operating Income? | -$687,205 | -$529,706 | -$677,765 | -$227,838 | -$24,871 |
| EBITDA? | -$247,484 | -$460,274 | -$596,383 | -$223,715 | -$24,864 |
| Income Before Tax | -$352,865 | -$715,546 | -$834,079 | -$227,838 | -$24,871 |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$352,865 | -$715,546 | -$834,079 | -$227,838 | -$24,871 |
| EPS? | $-0.00 | $-0.01 | $-0.01 | $-0.01 | $-0.01 |
| Diluted EPS? | $-0.00 | $-0.01 | $-0.01 | $-0.01 | $-0.01 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality